Products with Anticonvulsant bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2175 | Pregabalin |
| Pregabalin, a potent anticonvulsant agent, is used in treatment-resistant epileptic patients.Pregabalin (30 and 100mg/kg) presents central spinal but not central supraspinal antinociceptive effect and Pregabalin 100mg/kg shows peripheral antinociceptive effect. Pregabalin may be effective for the reduction of neuropathic pain, it improves postoperative analgesia compared with placebo at the expense of increased sedation and visual disturbances. | |
| BCN2306 | Methysticin |
| 1. Methysticin and yangonin show in vitro hepatotoxicity on human hepatocytes (HepG2) . 2. Methysticin and 7,8-dihydroMethysticin contribute to CYP1A1 induction. 3. Methysticin is a potent NF-kappaB inhibitor in kava with minimum toxicity. 4. Methysticin possesses anticonvulsant and neuroprotective properties, possibly by interfering with frequency potentiation. | |
| BCN2716 | Atropine sulfate |
| 1. Atropine sulfate causes a significant increase in IOP when given both topically and by intramuscular injection. | |
| BCN2962 | Guanosine |
| Guanosine and GMP show anticonvulsant properties, which may be related with antagonism of glutamate receptors; they also prevent seizures induced by quinolinic acid in mice.Guanosine protects against renal ischemic injury by replenishing GTP stores and preventing tubular apoptosis. | |
| BCN3438 | Paederosidic acid |
| Paederosidic acid has significant anti-tumor, anticonvulsant and sedative effects. Paederosidic acid increases brain gamma-aminobutyric acid and decreases glutamic acid in the brain, and it up-regulates expressions of GAD 65, may be a promising future therapeutic agent for treatment of epilepsy. | |
